Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

immune checkpoint inhibitor

  • You have access
    RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With Low PD-L1 Expression
    HIROAKI NAGAMINE, MASAKAZU YASHIRO, NAOKI YOSHIMOTO, MOTOHIRO IZUMI, AKIRA SUGIMOTO, KENJI NAKAHAMA, KOICHI OGAWA, YOSHIYA MATSUMOTO, KENJI SAWA, YOKO TANI, HIROYASU KANEDA, SHIGEKI MITSUOKA, KAZUHIRO YAMADA, TETSUYA WATANABE, KAZUHISA AASAI, KAZUHIRO FUKUMURA, AKILA MAYEDA and TOMOYA KAWAGUCHI
    Anticancer Research October 2023, 43 (10) 4663-4672; DOI: https://doi.org/10.21873/anticanres.16662
  • You have access
    Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study
    NOBUKI FURUBAYASHI, AKINORI MINATO, TAKAHITO NEGISHI, NAOTAKA SAKAMOTO, YOOHYUN SONG, YOSHIFUMI HORI, TOSHIHISA TOMODA, HIROYUKI MASAOKA, MIRII HARADA, SHINGO TAMURA, HIROKI KOBAYASHI, KAEDE MORIHARA, KENTARO KUROIWA, NARIHITO SEKI, NAOHIRO FUJIMOTO and MOTONOBU NAKAMURA
    Anticancer Research October 2023, 43 (10) 4701-4708; DOI: https://doi.org/10.21873/anticanres.16666
  • You have access
    Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study
    TAKURO OKADA, CHIHIRO FUSHIMI, TAKASHI MATSUKI, KUNIHIKO TOKASHIKI, HIDEAKI TAKAHASHI, ISAKU OKAMOTO, HIROKI SATO, TAKAHITO KONDO, KENJI HANYU, TAKUMA KISHIDA, TATSUYA ITO, GAI YAMASHITA, TATSUO MASUBUCHI, YUICHIRO TADA, KOKI MIURA, GO OMURA, TAKU YAMASHITA, NOBUHIKO ORIDATE and KIYOAKI TSUKAHARA
    Anticancer Research June 2023, 43 (6) 2717-2724; DOI: https://doi.org/10.21873/anticanres.16438
  • You have access
    Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
    HYERA KIM, DONG HYUN LIM, YONG SHIK KWON, MI AE KIM and KEON UK PARK
    Anticancer Research May 2023, 43 (5) 2343-2349; DOI: https://doi.org/10.21873/anticanres.16399
  • Open Access
    A Phase I/II Investigation of Safety and Efficacy of Nivolumab and nab-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway
    ERLINDA M. GORDON, NICOLE L. ANGEL, NADEZHDA OMELCHENKO, VICTORIA S. CHUA-ALCALA, ANIA MORADKHANI, DORIS QUON and STEVEN WONG
    Anticancer Research May 2023, 43 (5) 1993-2002; DOI: https://doi.org/10.21873/anticanres.16360
  • You have access
    Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma
    TAKESHI SANO, RIHITO AIZAWA, KATSUHIRO ITO, KIYONAO NAKAMURA, TAKASHI OGATA, MASASHI TAKEDA, AKIHIRO HAMADA, TAKASHI MATSUOKA, JIN KONO, YUKI KITA, KIMIHIKO MASUI, TAKAYUKI GOTO, ATSURO SAWADA, SHUSUKE AKAMATSU, OSAMU OGAWA, TAKASHI MIZOWAKI and TAKASHI KOBAYASHI
    Anticancer Research May 2023, 43 (5) 2119-2126; DOI: https://doi.org/10.21873/anticanres.16373
  • You have access
    Preclinical Platform Using a Triple-negative Breast Cancer Syngeneic Murine Model to Evaluate Immune Checkpoint Inhibitors
    NAR BAHADUR KATUWAL, NAHEE PARK, KAMAL PANDEY, MIN SIL KANG, SA DEOK HONG, MITHUN GHOSH, SEUL-GI KIM, YOUNG BIN CHO, JIN HUR, SEUNG KI KIM and YONG WHA MOON
    Anticancer Research January 2023, 43 (1) 85-95; DOI: https://doi.org/10.21873/anticanres.16137
  • You have access
    Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation
    SOU HATTORI, SHINICHIRO OKAUCHI, YUIKA SASATANI, GEN OHARA, KUNIHIKO MIYAZAKI, SHINYA SATO, TAKAHIDE KODAMA, TOSHIHIRO SHIOZAWA, HIROAKI SATOH and NOBUYUKI HIZAWA
    Anticancer Research September 2022, 42 (9) 4589-4595; DOI: https://doi.org/10.21873/anticanres.15962
  • You have access
    Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer
    SATOSHI INOUE, NAOTO SASSA, HIDEJI KAWANISHI, YURI YUGUCHI, TOMOHIDE SUZUKI, JUN NAGAYAMA, HIROTAKA MATSUI, YUDAI MIYATA, YUYA SOEDA, KOSUKE TOCHIGI, YUSHI YAMAUCHI, MOTOHIRO MAEDA, IKUO KOBAYASHI, RYOHEI HATTORI, YOSHIHISA MATSUKAWA and MASASHI KATO
    Anticancer Research July 2022, 42 (7) 3627-3636; DOI: https://doi.org/10.21873/anticanres.15851
  • You have access
    Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study
    TAKAFUMI NAKANO, RYUJI YASUMATSU, KAZUKI HASHIMOTO, RYOSUKE KUGA, TAKAHIRO HONGO, HIDETAKA YAMAMOTO, MIOKO MATSUO, TAKAHIRO WAKASAKI, RINA JIROMARU, TOMOMI MANAKO, SATOSHI TOH, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, YUICHIRO KURATOMI, MASAHIKO TAURA, TORANOSHIN TAKEUCHI and TAKASHI NAKAGAWA
    Anticancer Research July 2022, 42 (7) 3653-3664; DOI: https://doi.org/10.21873/anticanres.15854

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire